Sage Therapeutics, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 359
Rang # Quantité totale PI 3 600
Note d'activité PI 3,2/5.0    307
Rang # Activité PI 2 345
Symbole boursier
ISIN US78667J1088
Capitalisation 343M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

153 26
60 9
93 4
14
 
Dernier brevet 2025 - Neuroactive steroids for treatme...
Premier brevet 2012 - Neuroactive steroids, compositio...
Dernière marque 2025 - Sage Therapeutics
Première marque 2014 - SAGE THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 P/S Pharmaceutical preparations.
P/S Providing health information; Providing a web site featuring medical information
Invention Neuroactive steroids and their methods of use. Provided herein is a compound of Formula (I) or a...
2024 P/S Providing health information; patient support services relating to the treatment of postpartum de...
Invention 9(11)-unsaturated neuroactive steroids and their methods of use. Provided herein is a compound o...
Invention Compositions and methods for treating cns disorders. Provided herein is a compound of Formula (I...
P/S Pharmaceutical preparations
P/S Pharmaceutical preparations
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (I) and pharm...
Invention Methods of treating epilepsy or status epilepticus. Described herein are methods of treating epi...
Invention Neuroactive steroid formulations and methods of use thereof. Described herein are pharmaceutical ...
Invention Lymphatic system-targeting compounds. The disclosure provides lymphatic system-targeting compound...
P/S Pharmaceutical preparations. Providing health and medical information about diseases, disorders a...
Invention C7, c12, and c16 substituted neuroactive steroids and their methods of use. Described herein are...
Invention Neuroactive steroids and compositions thereof. Provided herein is a compound of Formula (I): P...
Invention Neuroactive steroids and their methods of use. 55c is carbon-bound substituted or unsubstituted h...
Invention Oxysterols and methods of use thereof. 8, and n are as defined herein. Compounds of the present i...
Invention Crystalline forms of a neuroactive steroid. This invention relates to crystalline forms of anhydr...
Invention Compositions and methods for treating cns disorders. Described herein are neuroactive steroids o...
Invention C7 substituted oxysterols and methods of use thereof. Compounds are provided according to Formul...
P/S Pharmaceutical preparations for use in the treatment of central nervous system diseases and disor...
Invention Neuroactive steroids and methods of use thereof. 3beta, 17beta disubstituted steroidal compounds...
2023 Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (I), and phar...
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (III): Comp...
Invention Negative nmda-modulating compounds and methods of use thereof. Compounds are provided according t...
Invention Method of screening compounds for treating cns disorders. Provided herein are screening methods ...
Invention Oxysterols and methods of use thereof. Compounds are provided according to Formula (I): Compou...
P/S House mark for pharmaceutical preparations Providing health and medical information about disease...
Invention Neuroactive steroids, compositions, and uses thereof. Provided herein are 19-nor C3, 3-disubstit...
Invention Compounds for treating cns disorders. Provided herein in part is a compound of Formula (I): or a...
Invention Deuterated neuroactive steroids. Provided herein is a deuterated compound of Formula (I) or a pha...
Invention Crystalline forms of a neuroactive steroid. This invention relates to crystalline solvated forms ...
Invention Neuroactive steroids, compositions, and uses thereof. Described herein are neuroactive steroids ...
Invention Compositions and methods for treating cns disorders. Provided herein is a compound of Formula (I)...
P/S Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, d...
Invention Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of c...
Invention Neuroactive steroids for treatment of gastrointestinal diseases or conditions. The present discl...
2022 Invention Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators. ...
Invention Neuroactive steroid for the treatment of huntington's disease. Provided herein are methods for i...
Invention Neuroactive steroids, compositions, and uses thereof. 3, A and L are as defined herein. Such comp...
Invention Deuterated positive nmda-modulating compounds and methods of use thereof. Deuterated compounds a...
Invention Positive nmda-modulating compounds and methods of use thereof. Compounds are provided according ...
P/S pharmaceutical preparations for the treatment of epilepsy, essential tremors, Parkinson's disease...
Invention Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's di...
Invention 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder ...
Invention Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a ...
Invention Treatment of essential tremor. The present invention provides a method of treating essential tre...
Invention A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorde...
Invention Use of neuroactive steroid for treatment of sexual dysfunction. This invention relates to method...
Invention Use of neuroactive steroids for treatment of sexual dysfunction. This invention relates to metho...
2021 Invention Neuroactive steroids and their methods of use. Provided herein is a compound of Formula (I), or ...
2020 P/S House mark for pharmaceutical preparations
P/S Pharmaceutical products.
2019 P/S Pharmaceutical preparations for the treatment of epilepsy, depression, Parkinson's disease, essen...
P/S house mark for pharmaceutical preparations
P/S Providing health and medical information about postpartum depression and treatment; patient suppo...
2018 P/S Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; p...
P/S Providing information in the fields of health, medicine, and pharmaceuticals related to depression
P/S Pharmaceutical preparations for the diagnosis and treatment of central nervous system disorders, ...
2017 P/S pharmaceutical preparations
P/S pharmaceutical preparations for the treatment of postpartum depression
P/S Prescription pharmaceutical preparations for the treatment of epilepsy, depression and postpartum...
P/S Pharmaceutical preparations. Pharmaceutical research and development services.